SGLT2 inhibitors and the changing landscape for treatment of diabetes
Shuangbo Liu,1 Anna Lam,2 Arslan Wazir,1 Asim N Cheema11Terrence Donnelly Heart Centre, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada; 2Division of Endocrinology, University of Alberta, Edmonton, Alberta, CanadaAbstract: Type 2 diabetes mellitus has become an epide...
Saved in:
Main Authors: | Liu S (Author), Lam A (Author), Wazir A (Author), Cheema AN (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2019-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Navigating the therapeutic landscape of SGLT2 inhibitors in diabetes management: exploring efficacy and emerging concerns
by: Farazul Hoda, et al.
Published: (2024) -
SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014) -
SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014) -
The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
by: Klaudia Kowalska, et al.
Published: (2022) -
Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus
by: Melpomeni Peppa, et al.
Published: (2023)